The present invention relates to the use of specific strains of Lactobacillus paracasei or of a composition comprising said strains for the prevention and/or treatment of a physiopathological condition related to/associated with Clostridium difficile infection, preferably intestinal infections, or so-called CD-associated disease (CDAD) or CD infection (CDI).
